BIOLIFE4D plans to strategically position itself at the center of an unprecedented convergence of regenerative medicine, stem cell biology, additive manufacturing (3D printing) and computing technology – all having reached a level of maturity whereby BIOLIFE4D is convinced that commercially viable bioprinting solutions can be created through optimization, not invention. History documents many examples of commercially viable businesses – even entirely new industries – that were born not from an invention itself, but from the optimization of an evolutionary process. Consider these examples:
In 1901 Ransom Eli Olds invented the assembly line;
in 1913 Henry Ford optimized a process that made it commercially viable.
In 1879 David Edward Hughes invented the radio;
in 1895 Guglielmo Marconi optimized a process that made it commercially viable.
In 1849 Antonio Meucci invented the telephone;
in 1876 Alexander Graham Bell optimized a process that made it commercially viable.
In 1802 Sir Humphry Davy invented the incandescent light;
in 1879 Thomas Edison optimized a process that made it commercially viable.
In 1608 Hans Lippershey invented the telescope;
in 1609 Galileo Galilei optimized a process that made it commercially viable.
In 2003 Thomas Boland invented the first bioprinter;
Today, BIOLIFE4D plans to optimize the process and make patient-specific, transplantable human organs commercially viable.
BIOLIFE4D’s objective is not to invent new technology, but rather to improve, optimize, adapt and capitalize on current technologies to create a commercially viable and sustainable process solution.
